Literature DB >> 33150599

Addressing Social Determinants of Liver Disease During the COVID-19 Pandemic and Beyond: A Call to Action.

Ani Kardashian1, Julius Wilder2,3, Norah A Terrault1, Jennifer C Price4.   

Abstract

The COVID-19 pandemic has exposed healthcare inequities in the USA and highlighted the importance of social conditions in shaping the health of persons. In the field of hepatology, social determinants of health (SDOH) are closely linked to disparities in liver disease prevalence, outcomes, and access to treatment. The economic disruption and physical distancing policies brought on by the COVID-19 pandemic have further exacerbated these disparities, and may have long-lasting health consequences for marginalized patients with chronic liver disease. There are several ways that hepatology providers can bridge the gap in health equity through addressing SDOH, extending from the individual to the community and societal levels. Interventions at the individual level include implementation of systematic screening for social barriers in our hepatology practices to identify gaps in the care cascade. At the community and societal levels, interventions include creating collaborative partnerships with public health workers to expand healthcare access to the community, increasing funding for research investigating the association of SDOH, health disparities, and liver disease, engaging in advocacy to support policy reform that tackles the upstream social determinants, and addressing racism and implicit bias. As hepatology practices adapt to the "new normal," now is the time for us to address our patients' social needs within the context of healthcare delivery and reimagine ways in which to provide care to best serve our most vulnerable patients with liver disease in the COVID-19 era and beyond.
© 2020 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2021        PMID: 33150599     DOI: 10.1002/hep.31605

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  5 in total

1.  Noninvasive Diagnosis of Nonalcoholic Steatohepatitis and Advanced Liver Fibrosis Using Machine Learning Methods: Comparative Study With Existing Quantitative Risk Scores.

Authors:  Yonghui Wu; Xi Yang; Heather L Morris; Matthew J Gurka; Elizabeth A Shenkman; Kenneth Cusi; Fernando Bril; William T Donahoo
Journal:  JMIR Med Inform       Date:  2022-06-06

Review 2.  Telemedicine and Health Disparities.

Authors:  Jennifer C Price; Dinee C Simpson
Journal:  Clin Liver Dis (Hoboken)       Date:  2022-01-28

3.  Outcome of COVID-19 in Patients With Autoimmune Hepatitis: An International Multicenter Study.

Authors:  Cumali Efe; Renumathy Dhanasekaran; Craig Lammert; Berat Ebik; Fatima Higuera-de la Tijera; Costica Aloman; Ali Rıza Calışkan; Mirta Peralta; Alessio Gerussi; Hatef Massoumi; Andreea M Catana; Murat Torgutalp; Tugrul Purnak; Cristina Rigamonti; Andres Jose Gomez Aldana; Nidah Khakoo; Hüseyin Kacmaz; Leyla Nazal; Shalom Frager; Nurhan Demir; Kader Irak; Zeynep Melekoğlu Ellik; Yasemin Balaban; Kadri Atay; Fatih Eren; Laura Cristoferi; Ersin Batıbay; Álvaro Urzua; Romee Snijders; Murat Kıyıcı; Murat Akyıldız; Nazım Ekin; Rotonya M Carr; Murat Harputluoğlu; Ibrahim Hatemi; Manuel Mendizabal; Marcelo Silva; Ramazan Idilman; Marina Silveira; Joost P H Drenth; David N Assis; Einar Björnsson; James L Boyer; Pietro Invernizzi; Chyntia Levy; Thomas D Schiano; Ezequiel Ridruejo; Staffan Wahlin
Journal:  Hepatology       Date:  2021-06       Impact factor: 17.425

4.  Perceptions and patient care needs among hepatitis B patients during COVID-19.

Authors:  Sherrie Flynt Wallington; Min Jeong Jeon; T Angeline Nguyen; Choosonjargal Byambaa; Y Tony Yang; Daisy Le
Journal:  BMC Health Serv Res       Date:  2022-06-30       Impact factor: 2.908

5.  Area Deprivation Index and Gut-Brain Axis in Cirrhosis.

Authors:  Jasmohan S Bajaj; Andrew Fagan; Sara McGeorge; Richard K Sterling; Shari Rogal; Masoumeh Sikaroodi; Patrick M Gillevet
Journal:  Clin Transl Gastroenterol       Date:  2022-06-01       Impact factor: 4.396

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.